The investigational new drug application (IND) acceptance will permit Metastatix to commence Phase I clinical studies in the US to determine the safety and tolerability of MSX-122 for the treatment of solid tumors.
Using technology licensed from Emory University, combined with world-class expertise in medicinal chemistry, Metastatix said that it is developing a robust portfolio of chemical compounds that block the CXCR4 receptor.
Carol Gallagher, president and CEO of Metastatix, said: “The credit for Metastatix’s rapid development path goes to our very talented team. We are very pleased to have produced a viable candidate for treating a disease as devastating as cancer in the two years since the company’s founding.”